Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab subcutaneous trial in adults with systemic sclerosis-associated interstitial lung disease
2023-503219-14-01Phase 3Authorised
- Sponsor
- GSK
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) comparing Belimumab with Placebo (2 arms). Primary endpoint: Absolute change from baseline in forced vital capacity. Planned start May 2024; status: authorised.
02
Drugs
belimumab
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on 2023-503219-14-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503219-14-01.